Thomas C R
Obstet Gynecol. 1976 Mar;47(3):304-8.
In a parallel study conducted over a 1-year period, involivng 460 private prenatal patients, the effect of routine prenatal phenobarbital for the prevention of neonatal jaundice was evaluated. The incidence of significant jaundice (bilirubin levels greater than or equal to 10 mg/100 ml) occurred in 4.1% of the 221 test patients compared to 16.3% of the 239 control patients. No significant complications resulted from the drug therapy, and the newborn infants demonstrated no adverse effects attributable to the phenobarbital. Mothers who were given prophylactic phenobarbital took their infants home earlier, less often brought infants back to the hospital for photo-therapy, and spent fewer dollars for their total medical care than their control conterparts. Routine phenobarbital prophylaxis was found to be a safe, effective, and economic method of preventing hyperbilirubinemia in the newborn.
在一项为期1年的平行研究中，涉及460名私立产前患者，评估了常规产前使用苯巴比妥预防新生儿黄疸的效果。221名试验患者中有4.1%发生了显著黄疸（胆红素水平大于或等于10mg/100ml），而239名对照患者中有16.3%发生了显著黄疸。药物治疗未导致明显并发症，新生儿未表现出归因于苯巴比妥的不良反应。接受预防性苯巴比妥治疗的母亲更早带婴儿回家，更少带婴儿回医院进行光疗，并且在总医疗护理上花费的钱比对照组母亲少。发现常规苯巴比妥预防是预防新生儿高胆红素血症的一种安全、有效且经济的方法。
